PFM Health Sciences’s ESSA Pharma EPIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,742,936
Closed -$16.6M 94
2024
Q3
$16.6M Sell
2,742,936
-222,506
-8% -$1.22M 0.94% 32
2024
Q2
$15.6M Sell
2,965,442
-14,978
-0.5% -$95.2K 0.77% 38
2024
Q1
$25.3M Sell
2,980,420
-282,080
-9% -$2.46M 1.19% 31
2023
Q4
$21.5M Sell
3,262,500
-936,753
-22% -$4.61M 1.29% 28
2023
Q3
$13M Sell
4,199,253
-5,700
-0.1% -$16.4K 0.61% 50
2023
Q2
$11.4M Buy
4,204,953
+43,492
+1% +$128K 0.44% 56
2023
Q1
$12.4M Buy
4,161,461
+317,129
+8% +$932K 0.55% 56
2022
Q4
$9.69M Buy
3,844,332
+2,366,080
+160% +$6.79M 0.35% 69
2022
Q3
$2.69M Buy
1,478,252
+516,536
+54% +$1.36M 0.1% 80
2022
Q2
$3.03M Buy
+961,716
New +$5.37M 0.12% 78

Other funds holding EPIX

PFM Health Sciences's EPIX Position: Q4 2024 in Review

PFM Health Sciences sold out of ESSA Pharma (EPIX) in Q4 2024, closing a stake of 2,742,936 shares — an estimated $16.6M sold.

PFM Health Sciences first reported a position in EPIX in Q2 2022 and held it in 10 quarters. The position peaked at $25.3M in Q1 2024. 46 funds tracked by Wall St. Rank hold EPIX as of Q4 2024.

  • PFM Health Sciences reported no remaining ESSA Pharma position as of Q4 2024 after selling out during the quarter.
  • PFM Health Sciences sold 2,742,936 ESSA Pharma shares in Q4 2024, an estimated $16.6M.
  • PFM Health Sciences first reported a position in ESSA Pharma in Q2 2022 and held it in 10 quarters.
  • PFM Health Sciences's ESSA Pharma position peaked at $25.3M in Q1 2024.
  • 46 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.